1. Home
  2. AZTR vs CDT Comparison

AZTR vs CDT Comparison

Compare AZTR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AZTR
  • CDT
  • Stock Information
  • Founded
  • AZTR 2014
  • CDT 2019
  • Country
  • AZTR United States
  • CDT United States
  • Employees
  • AZTR N/A
  • CDT N/A
  • Industry
  • AZTR Biotechnology: Pharmaceutical Preparations
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • AZTR Health Care
  • CDT Health Care
  • Exchange
  • AZTR Nasdaq
  • CDT Nasdaq
  • Market Cap
  • AZTR 3.7M
  • CDT 4.6M
  • IPO Year
  • AZTR 2023
  • CDT N/A
  • Fundamental
  • Price
  • AZTR $0.94
  • CDT $1.68
  • Analyst Decision
  • AZTR
  • CDT
  • Analyst Count
  • AZTR 0
  • CDT 0
  • Target Price
  • AZTR N/A
  • CDT N/A
  • AVG Volume (30 Days)
  • AZTR 1.5M
  • CDT 81.6K
  • Earning Date
  • AZTR 08-11-2025
  • CDT 08-14-2025
  • Dividend Yield
  • AZTR N/A
  • CDT N/A
  • EPS Growth
  • AZTR N/A
  • CDT N/A
  • EPS
  • AZTR N/A
  • CDT N/A
  • Revenue
  • AZTR N/A
  • CDT N/A
  • Revenue This Year
  • AZTR N/A
  • CDT N/A
  • Revenue Next Year
  • AZTR N/A
  • CDT N/A
  • P/E Ratio
  • AZTR N/A
  • CDT N/A
  • Revenue Growth
  • AZTR N/A
  • CDT N/A
  • 52 Week Low
  • AZTR $0.81
  • CDT $1.47
  • 52 Week High
  • AZTR $5.06
  • CDT $274.80
  • Technical
  • Relative Strength Index (RSI)
  • AZTR 31.60
  • CDT 38.23
  • Support Level
  • AZTR $0.81
  • CDT $1.47
  • Resistance Level
  • AZTR $1.07
  • CDT $1.85
  • Average True Range (ATR)
  • AZTR 0.11
  • CDT 0.11
  • MACD
  • AZTR 0.00
  • CDT 0.02
  • Stochastic Oscillator
  • AZTR 22.02
  • CDT 48.84

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: